← FDA DRUG APPROVALS

FDA ANDA · ANDA091039

DAPTOMYCIN

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA091039
TYPE
ANDA
ORIGINAL APPROVAL
2016-03-25
LATEST ACTION
2019-11-12
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

DAPTOMYCINPrescription
DAPTOMYCIN 500MG/VIAL · POWDER · INTRAVENOUS

Approval history

2019-11-12Labeling · Supplement 4 · standardAP
2019-11-12Labeling · Supplement 2 · standardAP
2019-11-12Labeling · Supplement 3 · standardAP
2016-12-21Labeling · Supplement 1 · standardAP
2016-03-25OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →